

## HM2023-43: A phase 2 trial of tafasitamab in combination with lenalidomide+rituximab in treatment-naïve follicular lymphoma and marginal zone lymphoma

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- confirmed marginal zone lymphoma - have not received systemic therapy for lymphoma - need treatment because of bulky disease, associated symptoms, or causing problems with vital organs (heart, spleen, lung) - see link to [clinicaltrials.gov](https://clinicaltrials.gov) for complete Inclusion criteria

---

**Exclusion Criteria:**

- active HIV, Hepatitis B, Hepatitis C - prior history of lenalidomide use - history of another cancer in the past 5 years - women who are pregnant or breastfeeding - see link to [clinicaltrials.gov](https://clinicaltrials.gov) for complete Exclusion criteria

### Conditions & Interventions

**Conditions:**

Cancer

**Keywords:**

Clinics and Surgery Center (CSC), Follicular Lymphoma

### More Information

**Description:** This study is to see if patients who get tafasitamab in addition to the standard regimen of lenalidomide and rituximab when they are just starting treatment are more likely to stay in remission after treatment than those who do not. We expect that participants will be in this research study for approximately 3 years total. Patients will be on active treatment for approximately 1 year.

**Study Contact:** Sanjal Desai - [desai171@umn.edu](mailto:desai171@umn.edu)

**Principal Investigator:** Sanjal Desai

**Phase:** PHASE2

**IRB Number:** STUDY00023899

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.